Edwards Lifesciences (NYSE:EW) Releases FY 2025 Earnings Guidance

Edwards Lifesciences (NYSE:EW) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided EPS guidance of 2.560-2.620 for the period, compared to the consensus EPS estimate of 2.590. The company issued revenue guidance of $6.0 billion-$6.0 billion, compared to the consensus revenue estimate of $6.0 billion.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Oppenheimer downgraded Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 8th. Truist Financial set a $92.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, December 5th. JPMorgan Chase & Co. raised Edwards Lifesciences from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $90.00 to $100.00 in a report on Thursday. The Goldman Sachs Group set a $104.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Raymond James Financial raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price for the company in a research report on Monday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.95.

Edwards Lifesciences Stock Down 0.1%

EW stock opened at $84.73 on Friday. The business has a 50-day simple moving average of $82.30 and a 200 day simple moving average of $79.22. The company has a market cap of $49.17 billion, a PE ratio of 36.52, a price-to-earnings-growth ratio of 3.81 and a beta of 0.97. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 52 week low of $65.94 and a 52 week high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.08. The business had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.Edwards Lifesciences’s revenue for the quarter was up 14.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Sell-side analysts anticipate that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 11,386 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $83.76, for a total transaction of $953,691.36. Following the sale, the vice president directly owned 38,970 shares in the company, valued at approximately $3,264,127.20. The trade was a 22.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $84.03, for a total transaction of $85,626.57. Following the completion of the transaction, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,848,828.06. This trade represents a 4.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 45,465 shares of company stock worth $3,804,610 in the last 90 days. Insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

A number of hedge funds have recently modified their holdings of EW. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the third quarter worth $25,000. Rakuten Securities Inc. lifted its holdings in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after buying an additional 302 shares during the period. Kelleher Financial Advisors bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at about $50,000. Chapman Financial Group LLC acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at about $63,000. Finally, Financial Life Planners acquired a new stake in shares of Edwards Lifesciences in the third quarter valued at about $93,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.